Piper Sandler lowered the firm’s price target on Fulgent Genetics to $25 from $28 and keeps a Neutral rating on the shares. The firm cites the company’s earnings results.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on FLGT:
